IDT Biologika

Photo
01.07.2024 • News

SK Bioscience Acquires Majority Stake in IDT Biologika

South Korea-headquartered contract development and manufacturing organization (CDMO) SK Bioscience plans to acquire a 60% stake in IDT Biologika, a German CDMO specialized in vaccines, gene and immune therapy and oncolytic viruses, from Klocke Group. Klocke will retain a 40% stake in IDT Biologika and thus remains the company's second-largest shareholder.

Photo
04.03.2022 • News

IDT Biologika and Exothera Join on Vaccine Scale-up

IDT Biologika, a German CDMO specialized in vaccines, gene and immune therapy and oncolytic viruses, is collaborating with Belgian CDMO Exothera on developing a large-scale manufacturing process for viral vector-based vaccines. The two firms are currently conducting a feasibility study focused on the Modified Vaccinia Ankara (MVA) virus as a first project to come out of IDT’s broad range of vector technologies.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.